CVS Continues Preferred Status For Harvoni Over Viekira Pak
This article was originally published in The Pink Sheet Daily
Executive Summary
With the release of its formulary exclusions for 2016, CVS Health continues to prefer Gilead's HCV treatment over AbbVie's; just last week, Express Scripts continued with the opposite.